CXCR4 and HIV infectious disease: However, at present only clinical trials in inhibition of HIV infection [the CCR5 antagonist maraviroc (19, 20)] and mobilization of stem cells [the CXCR4 antagonist plerixafor (21, 22)] have successfully led to marketed drugs.